Effect of intravitreal Ranibizumab treatment in polypoidal choroidal vasculopathy with different types
10.3980/j.issn.1672-5123.2016.11.23
- VernacularTitle:雷珠单抗治疗息肉状脉络膜血管病变的疗效观察
- Author:
Da-Liang, WANG
;
Man, LUO
;
Cha-Ying, MIAO
;
Su-Rong, LUO
- Publication Type:Journal Article
- Keywords:
ranibizumab;
polypoidal choroidal vasculopathy;
best corrected visual acuity;
central retinal thickness
- From:
International Eye Science
2016;16(11):2079-2081
- CountryChina
- Language:Chinese
-
Abstract:
AIM: To investigate the efficiency of intravitreal ranibizumab therapy ( IVR ) for polypoidal choroidal vasculopathy ( PCV) in single or multiple polyps.
METHODS: A total 63 patients diagnosed with PCV in Shaoxing City People's Hospital from May 2013 to May 2015 were enrolled and divided into single polyp group and multiple polyps group. All patients received intravitreal ranibizumab 3 monthly and were followed up for 12mo. Observe the changes of best corrected visual acuity ( BCVA ) and central retinal thickness ( CRT ) at different time points.
RESULTS: The single polyps group exhibited a better BCVA, shorter greatest linear dimension, and lower prevalence of fibro - vascular pigment epithelial detachment compared with the multiple polyp group before treatment (P<0. 05). Significant difference of BCVA were observed at 3, 6 and 12mo between the two groups (P<0. 05). BCVA at 3, 6, 12mo was significantly better than that at baseline in single polyps group. The single polyp group exhibited a significantly thinner CRT at 6 and 12mo compared with multiple polyps group (P<0. 05). The single polyp group showed improvement in CRT over the followed up period(P<0. 05). The CRT in multiple polyps group at 3 and 6mo significantly decreased compared with preoperative (P<0. 05).
CONCLUSION: IVR meet better result in PCV patients with multiple polyp and polyp numbers may be valuable to prognosis.
